US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

NEW DELHI – U.S. drugmaker Amgen plans to invest approximately $200 million this year in its new technology center located in southern India, with additional investments anticipated, CEO Robert ...

On World Rare Diseases Day, read on to learn more about Myasthenia Gravis, a complex autoimmune disorder that requires careful management. Early diagnosis and appropriate treatment can help ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...